Brokerages Set BioAge Labs, Inc. (NASDAQ:BIOA) Price Target at $36.57

BioAge Labs, Inc. (NASDAQ:BIOA) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $36.5714.

Several equities analysts have issued reports on BIOA shares. Wall Street Zen upgraded shares of BioAge Labs from a “strong sell” rating to a “sell” rating in a research note on Sunday. Roth Capital reissued a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a report on Wednesday. BTIG Research reissued a “buy” rating and issued a $40.00 target price on shares of BioAge Labs in a research report on Tuesday, September 8th. Needham & Company LLC dropped their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st.

Institutional Trading of BioAge Labs

Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in BioAge Labs during the 2nd quarter worth $84,000. CWM LLC increased its stake in BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of BioAge Labs in the third quarter valued at about $27,000. State of Wyoming purchased a new stake in shares of BioAge Labs in the second quarter valued at about $154,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of BioAge Labs during the second quarter worth about $234,000.

BioAge Labs Trading Down 1.8%

BIOA stock opened at $8.49 on Friday. The stock has a market cap of $389.69 million, a P/E ratio of -3.57 and a beta of 0.94. BioAge Labs has a twelve month low of $4.68 and a twelve month high of $25.95. The company’s 50 day moving average is $14.93 and its two-hundred day moving average is $17.45.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The firm had revenue of $2.45 million for the quarter. On average, equities research analysts predict that BioAge Labs will post -2.45 earnings per share for the current year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.